# Epidermal Growth Factor Receptor Inhibition for Keratinopathies

> **NCT06545695** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Northwestern University** · enrollment: 44 (estimated)

## Conditions studied

- Epidermolytic Ichthyosis
- Palmoplantar Keratoderma
- Pachyonychia Congenita

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT06545695
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-07-01
- **Primary completion:** 2031-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06545695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06545695, "Epidermal Growth Factor Receptor Inhibition for Keratinopathies". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06545695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*